Montejano, R., de la Calle-Prieto, F., Velasco, M., Guijarro, C., Queiruga-Parada, J., Jimenez-Gonzalez, M., . . . Arribas, J. (2023). Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial.
Citación estilo ChicagoMontejano, R., et al. Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients At High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial. 2023.
Cita MLAMontejano, R., et al. Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients At High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial. 2023.
Precaución: Estas citas no son 100% exactas.